AAPL   318.15 (-0.03%)
GOOGL   1,425.10 (+0.48%)
NVDA   343.56 (+1.20%)
CGC   17.33 (-20.21%)
BABA   198.35 (-0.57%)
MU   46.52 (+0.11%)
GE   6.56 (-3.24%)
TSLA   811.17 (+0.67%)
T   30.70 (-1.16%)
ACB   14.12 (-7.95%)
DIS   115.15 (-1.37%)
BAC   24.49 (-1.49%)
BA   145.51 (-2.88%)
AAPL   318.15 (-0.03%)
GOOGL   1,425.10 (+0.48%)
NVDA   343.56 (+1.20%)
CGC   17.33 (-20.21%)
BABA   198.35 (-0.57%)
MU   46.52 (+0.11%)
GE   6.56 (-3.24%)
TSLA   811.17 (+0.67%)
T   30.70 (-1.16%)
ACB   14.12 (-7.95%)
DIS   115.15 (-1.37%)
BAC   24.49 (-1.49%)
BA   145.51 (-2.88%)
AAPL   318.15 (-0.03%)
GOOGL   1,425.10 (+0.48%)
NVDA   343.56 (+1.20%)
CGC   17.33 (-20.21%)
BABA   198.35 (-0.57%)
MU   46.52 (+0.11%)
GE   6.56 (-3.24%)
TSLA   811.17 (+0.67%)
T   30.70 (-1.16%)
ACB   14.12 (-7.95%)
DIS   115.15 (-1.37%)
BAC   24.49 (-1.49%)
BA   145.51 (-2.88%)
AAPL   318.15 (-0.03%)
GOOGL   1,425.10 (+0.48%)
NVDA   343.56 (+1.20%)
CGC   17.33 (-20.21%)
BABA   198.35 (-0.57%)
MU   46.52 (+0.11%)
GE   6.56 (-3.24%)
TSLA   811.17 (+0.67%)
T   30.70 (-1.16%)
ACB   14.12 (-7.95%)
DIS   115.15 (-1.37%)
BAC   24.49 (-1.49%)
BA   145.51 (-2.88%)
Log in

NYSE:NGVTIngevity Stock Price, Forecast & News

$51.92
-1.62 (-3.03 %)
(As of 05/29/2020 11:16 AM ET)
Add
Compare
Today's Range
$51.28
Now: $51.92
$52.78
50-Day Range
$37.70
MA: $44.84
$57.80
52-Week Range
$24.92
Now: $51.92
$108.20
Volume6,313 shs
Average Volume481,951 shs
Market Capitalization$2.14 billion
P/E Ratio10.64
Dividend YieldN/A
Beta2.47
Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment develops, manufactures, and sells a range of specialty chemicals derived from co-products of the Kraft pulping process and caprolactone. This segment's products are used in various applications comprising pavement preservation, pavement adhesion promotion and warm mix paving, oil well service additives, oil production and downstream application chemicals, printing inks, adhesives, agrochemicals, lubricants and industrial intermediates, coatings resins, elastomers, adhesives, and bio-plastics. Ingevity Corporation was incorporated in 2015 and is headquartered in North Charleston, South Carolina.
Read More
Ingevity logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.48 out of 5 stars


Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustryN/A
SectorBasic Materials
Previous SymbolNASDAQ:NGVT
CUSIPN/A
Phone843-740-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.29 billion
Cash Flow$6.29 per share
Book Value$12.18 per share

Profitability

Net Income$183.70 million

Miscellaneous

Employees1,850
Market Cap$2.14 billion
Next Earnings Date7/22/2020 (Estimated)
OptionableOptionable

Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for NGVT and its competitors with MarketBeat's FREE daily newsletter.

Ingevity (NYSE:NGVT) Frequently Asked Questions

How has Ingevity's stock been impacted by COVID-19 (Coronavirus)?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NGVT stock has increased by 33.7% and is now trading at $51.87. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ingevity?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ingevity.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Ingevity.

How were Ingevity's earnings last quarter?

Ingevity Corp (NYSE:NGVT) issued its quarterly earnings results on Wednesday, April, 29th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.84 by $0.28. The business had revenue of $288.20 million for the quarter, compared to analyst estimates of $263.61 million. Ingevity had a return on equity of 45.48% and a net margin of 15.82%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.99 EPS. View Ingevity's earnings history.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity issued an update on its second quarter 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $246.96-264.6 million, compared to the consensus revenue estimate of $325.64 million.

What price target have analysts set for NGVT?

7 analysts have issued 1 year price objectives for Ingevity's shares. Their forecasts range from $42.00 to $107.00. On average, they expect Ingevity's stock price to reach $73.14 in the next year. This suggests a possible upside of 41.0% from the stock's current price. View analysts' price targets for Ingevity.

Has Ingevity been receiving favorable news coverage?

Media coverage about NGVT stock has trended somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ingevity earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutIngevity.

Who are some of Ingevity's key competitors?

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), Dominion Energy (D), General Electric (GE), Quaker Chemical (KWR), Boeing (BA), Alibaba Group (BABA) and Walt Disney (DIS).

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • Mr. D. Michael Wilson, Pres, CEO & Director (Age 56)
  • Mr. John C. Fortson, Exec. VP, CFO & Treasurer (Age 52)
  • Ms. Katherine Pryor Burgeson, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Stuart Edward Woodcock Jr., Exec. VP & Pres of Performance Materials (Age 53)
  • Mr. Michael P. Smith, Exec. VP and Pres of Performance Chemicals, Strategy & Bus. Devel. (Age 58)

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.48%), Wellington Management Group LLP (3.76%), Franklin Resources Inc. (3.46%), State Street Corp (3.30%), Ardevora Asset Management LLP (2.19%) and Alliancebernstein L.P. (1.90%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Katherine Pryor Burgeson, Michael P Smith, Phillip John Platt and Richard B Kelson. View institutional ownership trends for Ingevity.

Which major investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Wells Fargo & Company MN, Massachusetts Financial Services Co. MA, Wellington Management Group LLP, Russell Investments Group Ltd., BlackRock Inc., and New York State Common Retirement Fund. View insider buying and selling activity for Ingevity.

Which major investors are buying Ingevity stock?

NGVT stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Two Sigma Investments LP, Two Sigma Advisers LP, Deutsche Bank AG, Aperture Investors LLC, Canada Pension Plan Investment Board, Rice Hall James & Associates LLC, and London Co. of Virginia. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson. View insider buying and selling activity for Ingevity.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $51.87.

How big of a company is Ingevity?

Ingevity has a market capitalization of $2.14 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,850 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

How can I contact Ingevity?

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.